Any feedback?
Literature summary for 3.4.24.87 extracted from
- Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy? (2005), J. Biol. Chem., 280, 39934-39941.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | in order to develop new strategies for improving the diagnosis and treatment of thrombotic thrombocytopenic purpura, this study systemically analyzed a series of ADAMTS13 mutant proteins to identify variant forms that are proteolytically active and yet resistant to suppression by inhibitory antibodies. A deficiency ofADAMTS13, due to mutations in the ADAMTS13 gene or the presence of antibodies that inhibit the activity of the protease,causes thrombotic thrombocytopenic purpura. Plasma therapy, the conventional therapy for TTP, may cause serious adverse reactions and is ineffective in some patients | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | Q76LX8 | ADAMTS-13 precursor | - |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| von Willebrand factor + H2O | - |
Homo sapiens | ? | - |
? |  |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
